Your email has been successfully added to our mailing list.

×
0 0 -0.0271739130434783 -0.0543478260869566 -0.0760869565217391 -0.0815217391304347 -0.103260869565217 -0.108695652173913
Stock impact report

pSivida Out-licenses EMEA Rights for Durasert™ Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimer...

PSIVIDA (PSDV) 
Last psivida earnings: 2/7 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.psivida.com
Company Research Source: GlobeNewswire
WATERTOWN, Mass., July 10, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced an amendment of its exclusive license and collaboration agreement with Alimera Sciences, Inc. (NASDAQ:ALIM) that grants Alimera rights to pSivida’s Durasert™ three-year treatment for posterior segment uveitis (Durasert) in Europe, the Middle East and Africa (EMEA). With this license, Alimera plans to pursue a secondary indication for ILUVIEN for posterior segment uveitis in EMEA, which could accelerate the uveitis indication approval as well as commercialization.  pSivida retains commercialization rights for posterior segment uveitis in all other countries, including the United States.  The amended agreement also modifies the companies’ existing global licensing agreement for ILUVIEN for the treatment of diabetic macular edema (DME).  Key terms of the restructured global licensing agreement for IL Show less Read more
Impact Snapshot
Event Time:
PSDV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for PSDV alerts
Opt-in for
PSDV alerts

from News Quantified
Opt-in for
PSDV alerts

from News Quantified